[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652482":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":32,"responsibleParty":47,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":10,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Al-Azhar University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Tadalafil 5 mg once daily",null,"Adult men with predominantly vasculogenic erectile dysfunction who are eligible for tadalafil 5 mg once daily and enrolled in this prospective cohort study.",[13],"Drug: Tadalafil 5mg",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Tadalafil 5mg","All enrolled participants will receive tadalafil 5 mg orally once daily for 12 weeks as part of clinical management.",[9],[21],"PDE5 inhibitor",[23],{"name":24,"affiliation":25,"role":26},"Abul-fotouh Ahmed","Department of Urology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt","PRINCIPAL_INVESTIGATOR",[28],{"name":24,"role":29,"phone":30,"phoneExt":10,"email":31},"CONTACT","+201001066756","abulfotouhahmed@yahoo.com",[33],{"facility":34,"status":35,"city":36,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Department of Urology, Al-Hussein and Sayed Galal University Hospitals, Al-Azhar University","RECRUITING","Cairo","Egypt","EG",{"type":40,"coordinates":41},"Point",[42,43],31.24967,30.06263,{"lat":43,"lon":42},[46],{"name":24,"role":29,"phone":30,"phoneExt":10,"email":31},{"type":26,"investigatorFullName":24,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Professor of Urology","100652482","endothelial-markers-and-tadalafil-response-100652482",false,"NCT07773103","Endothelial Markers and Tadalafil Response","Endothelial Dysfunction Markers as Predictors of Clinical Response to Daily Tadalafil in Men With Vasculogenic Erectile Dysfunction","Inclusion Criteria:\n\n* Participants must fulfill all of the following:\n\n  * Men aged 30 to 70 years.\n  * ED lasting at least 3 months.\n  * IIEF-5\u002FSHIM score of 21 or less or clinically documented ED.\n  * Clinical features suggesting predominantly vasculogenic ED.\n  * Sexually active or willing to attempt sexual intercourse during the study.\n  * Able to complete the study questionnaires.\n  * Willing to take tadalafil 5 mg once daily for 12 weeks.\n  * Able to provide written informed consent.\n  * Willing to avoid other ED treatments during the study unless medically necessary.\n\nExclusion Criteria:\n\n* Patients will be excluded if they have:\n\n  * ED primarily attributed to psychogenic causes.\n  * Predominantly neurogenic ED.\n  * Severe untreated hypogonadism likely to be the primary cause of ED.\n  * Untreated hyperprolactinemia or another major endocrine disorder.\n  * Significant penile anatomical abnormality interfering with intercourse, including severe Peyronie's disease.\n  * Previous radical pelvic surgery or pelvic radiotherapy.\n  * Active urinary or genital infection.\n  * Unstable angina or unstable cardiovascular disease.\n  * Recent myocardial infarction or stroke.\n  * Uncontrolled hypertension or clinically significant hypotension.\n  * Severe renal impairment requiring an alternative tadalafil regimen.\n  * Severe hepatic impairment.\n  * Active malignancy or expected survival of less than one year.\n  * Major psychiatric illness, cognitive impairment or inability to comply with follow-up.\n  * Current use of another PDE5 inhibitor or intracavernosal therapy that cannot be discontinued.\n  * Concomitant use of organic nitrates, nitric oxide donors or nicorandil.\n  * Known hypersensitivity to tadalafil.\n  * Participation in another study that may affect erectile function or vascular measurements.\n  * Refusal or inability to provide informed consent.","MALE","30 Years","70 Years",{"count":60,"type":61},120,"ESTIMATED","OBSERVATIONAL","This prospective cohort study will recruit eligible men attending the Urology\u002FAndrology outpatient clinic. Baseline assessment will include demographic and clinical data, cardiovascular risk assessment, erectile-function questionnaires, routine laboratory investigations, brachial artery flow-mediated dilatation, carotid intima-media thickness, and selected circulating endothelial biomarkers including endothelin-1, nitrite\u002Fnitrate, high-sensitivity C-reactive protein, soluble vascular cell adhesion molecule-1, and soluble intercellular adhesion molecule-1. All participants will receive tadalafil 5 mg once daily for 12 weeks. Erectile function, adherence, and adverse events will be assessed during follow-up. The primary outcome will be clinical response at 12 weeks, defined as an improvement of at least 4 points in the IIEF-EF domain together with a positive response to the Global Assessment Question.",[65],"Vasculogenic Erectile Dysfunction","2026-08-19",{"date":68,"type":69},"2026-08-20","ACTUAL",{"date":66,"type":69},{"date":72,"type":61},"2028-12",{"name":5,"class":6},1]